Inclusion Criteria:

- Subjects with suspected primary or metastatic RCC (stage 1-IV) with planned
nephrectomy or partial nephrectomy.

- ECOG performance status ≤1

- Normal renal, hepatic, and hematologic function at the time of enrollment as
evidenced by:

- Serum creatinine level ≤1.5 the upper limits of normal (ULN)

- Serum total bilirubin level ≤1.5 X ULN

- White blood cell count > or = 3.5x109/ml per ml and platelet count ≥ 100x109 per ml

- Age >18 years.

- Ability to understand and the willingness to sign a written informed consent
document.

Exclusion Criteria:

- Subjects who have received chemotherapy for any diagnosis within 12 months prior to
study entry.

- Prior use of radiotherapy or investigational agents for RCC.

- Concurrent malignancies with evidence of active or measurable disease except
non-melanoma skin cancer

- Inability to adhere to study and/or follow-up procedures

- History of allergic reactions or hypersensitivity to the study drug
(hydroxychloroquine) or current therapy with the study drug for other reasons.

- Other concurrent experimental therapy.

- The effects of HC on the developing human fetus are unknown. For this reason women of
child-bearing potential and men must agree to use adequate contraception (hormonal or
barrier method of birth control; abstinence) prior to study entry and for the
duration of study participation. All females of childbearing potential must have a
blood test or urine study within two weeks prior to registration to rule out
pregnancy. Should a woman become pregnant while participating in this study, she
should inform her treating physician immediately. If a man impregnates a woman while
participating in this study, he should inform his treating physician immediately as
well.

- HIV-positive patients are not excluded from the study. However, for patients
receiving combination anti-retroviral therapy, the potential impact of
pharmacokinetic interactions with HC is unknown. Therefore, HIV-positive patients
actively receiving anti-retroviral therapy are excluded from the study.

- Patients with psoriasis are ineligible unless the disease is well controlled and they
are under the care of a specialist who agrees to monitor the patient for
exacerbations.

- Patients requiring the use of enzyme-inducing anti-epileptic medication that
includes: phenytoin, carbamazepine, phenobarbital, primidone or oxcarbazepine are
excluded. Hydroxychloroquine is known to affect the CYP2D6 metabolic pathway. A
list of drugs with potential interaction is included in Appendix H.

- Patients with previously documented macular degeneration or diabetic retinopathy are
excluded.

- Patients with known glucose-6-phosphate dehydrogenase (GP6D) deficiency

- EKG with QTc >500 msec at baseline (average of 3 determinations at 10 minutes
interval). Subjects with ventricular pacemaker for whom QT interval is not measurable
will be eligible on a case-by-case basis.